Pathogenicity and drug resistance in Candida albicans and other yeast species

Acta Microbiologica et Immunologica Hungarica

Volumn 54, Issue 3, 2007, Pages 201-235

  Mishra, Nagendra Nath ^a   Prasad, Tulika ^b   Sharma, Neeraj ^c   Payasi, Anurag ^a   Prasad, Rajendra ^b   Gupta, Dwijendra K ^d   Singh, Randhir ^a  

^a Seth J M Institute of Engineering and Technology   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^d UNIVERSITY OF ALLAHABAD   (India)

Author keywords

ABC transporters; Biofilm; Candida; Drug resistance; Efflux pump; Efflux pumps

Indexed keywords

CANDIDA; CANDIDA ALBICANS;

EID: 34548429972     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.54.2007.3.1     Document Type: Review

References (154)

1. Lemar, K. M., Turner, M. P., Lloyd, D.: Garlic (Allium sativam) as an anti-Candida agent: a comparison of the efficacy of fresh garlic and freeze-dried extracts. J Appl Microbiol 93, 398-405 (2002).
2. Gozalbo, D., Roig, P., Villamón, E., Gil, M. L.: Candida and Candidiasis: The cell wall as a potential molecular target for antifungal therapy. Curr Drug Targets Infect Disord 4, 117-135 (2004).
3. Prasad, R., Kapoor, K.: Multidrug resistance in yeast Candida. Int Rev Cyt 242, 215-248 (2005).
4. Bodey, G. P.: Candidiasis. Pathogenesis, Diagnosis and Treatment, Raven Press, New York (1993).
5. Casadevall, A Cassone, A., Bistoni, F., Cutler, J. E., Magliani, W., Murphy, J. W., Polonelli, L., Romani, L.: Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: An ongoing dilemma or an unnecessary dispute. Med Mycol 36, 95-105 (1998).
6. Romani, L.: Immunity to fungal infections. Nat Rev Immunol 4, 1-13 (2004).
7. Cutler, J. E.: Putative virulence factors of Candida albicans. Annu Rev Microbiol 45, 187-218 (1991).
8. Calderone, R. A.: Candida and Candidiasis. ASM Press, Washington (2002).
9. Chaffin, W. L., López-Ribot, J. L., Casanova, M., Gozalbo, D., Martínez, J. P.: Cell wall and secreted proteins of Candida albicans: Identification, function, and expression. Microbiol Mol Biol Rev 62, 130-180 (1998).
10. Martínez, J. P. Gil, M. L., López-Ribot M. L., Chaffin, W. L.: Serologic; response to cell wall mannoproteins and proteins of Candida albicans. Clin Microbiol Rev 11, 121-141 (1998).
11. Soll, D. R.: High-frequency switching in Candida albicans. Clin Microbiol Rev 5, 183-203 (1992).
12. Naglik, J. R., Challacombe, S. J., Hube, B.: Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67, 400-428 (2003).
13. Brown, A. J., Gow, N. A. R.: Regulatory networks controlling Candida albicans morphogenesis. Trends Microbiol 7, 333-338 (1999).
14. Ernst, J.: Transcription factors in Candida albicans - environmental control of morphogenesis. Microbiol 146, 1763-1774 (2000).
15. Soll, D. R.: Gene regulation during high-frequency switching in Candida albicans. Microbiol 143, 279-288 (1997).
16. Cutler, J. E.: Putative virulence factors of Candida albicans. Annu Rev Microbiol 45, 187-218 (1991).
17. Calderone, R. A.: Candida and Candidiasis. ASM Press, Washington (2002).
18. Gooday, G. W., in: The Growing Fungus. Eds. Gow, N. A. R., Gadd, G. M. Chapman and Hall, London, 41-74 (1995).
19. Tavares, D., Salvador, A., Ferreira, P., Arala-Chaves, M. P.: Immunological activities of a Candida albicans protein which plays an important role in the survival of the microorganism in the host Infect Immun 61, 1881 (1993).
20. Tsuboi, R., Komatsuzaki, H., Ogawa, H.: Induction of an extracellular esterase from Candida albicans and some of its properties. Infect Immun 64, 2936 (1996).
21. Sturtevant, J., Dixon, F., Wadsworth, E., Latge, J. P., Zhao, X. J., Calderone, R.: Identification and cloning of GCA1, a gene which encodes a cell wall glucoamylase from Candida albicans. Med Mycol 37, 357-366 (1999).
22. Douglas, L. J., in: New Strategies in Fungal Disease. Eds. Bennet, J. E., Hay, R. J., Peterson, P. K. Churchill. Livingstone Inc, New York, 34-50 (1992).
23. Calderone, R. A.: Recognition between Candida albicans and host cells. Trends Microbiol 1, 55-58 (1993).
24. Calderone, R., Diamond, R., Senet, J. M., Warmington, J., Filler, S., Edwards, J. E.: Host cell-fungal cell interactions. J Med Vet Mycol 32, 151-168 (1994).
25. Klotz, S. A.: Plasma and extracellular matrix proteins mediate in the fate of Candida albicans in the human host. Medical Hypotheses 42, 328-334 (1994).
26. Hostetter, M. K.: Integrin-like proteins in Candida spp. and other microorganisms. Fungal Genet Biol 28, 135-145 (1999).
27. Fukazawa, Y., Kagaya, K.: Molecular basis of adhesion of Candida albicans. J Med Vet Mycol 35, 87-99 (1997).
28. Hostetter, M.: Adhesins and ligands involved in the interaction of Candida spp. with epithelial and endothelial surfaces. Clin Microbiol Rev 7, 29-42 (1994).
29. Alonso, R., Lopis, I., Flores, C., Murgui, A., Timoneda, J.: Different adhesins for type IV collagen on Candida albicans: Identification of a lectin-like adhesin recognizing the 7S(IV) domain. Microbiol 147, 1971-1981 (2001).
30. Holmes, A. R., Bandara, B. M., Cannon, R. D.: Saliva promotes Candida albicans adherence to human epithelial cells. J Dent Res 81, 28-32 (2002).
31. Meri, T., Hartmann, A., Lenk, D., Eck, R., Wurzner, R., Hellwage, J., Meri, S., Zipfel, P. F.: The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun 70, 5185-5192 (2002).
32. Gale, C. A. Bendel, C. M., McClellan, M., Hauser, M., Becker, J. M., Berman, J., Hostetter, M. K.: Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science 279, 1355-1358 (1998).
33. Crowe, J. D., Sievwright, I. K., Auld, G. C., Moore, N. R., Gow, N. A. R., Booth, N. A.: Candida albicans binds human plasminogen: Identification of eight plasminogen-binding proteins. Mol Mcrobiol 47, 1637-1651 (2003).
34. Hoyer, L. L.: The ALS gene family of Candida albicans. Trends Microbiol 9, 176-180 (2001).
35. Sundstrom, P.: Adhesion in Candida spp. Cell Microbiol 4, 461-469 (2002).
36. Gaur, N. K. Smith, R. L., Klotz, S. A.: Candida albicans and Saccharomyces cerevisiae expressing ALA1/ALS5 adhere to accessible threonine, serine or alanine patches. Cell Commun Adhes 9, 45-57 (2002).
37. Staab, J. F., Bradway, S. D., Fidel, P. L., Sundstrom, P.: Adhesive and mammalian transglutaminase substrate properties of Candida albicans HWP1. Science 283, 1535-1538 (1999).
38. Fu, Y., Ibrahim, A. S., Sheppard, D. C., Chen, Y. C., French, S. W., Cutler, J. E., Filler, S. G., Edwards, J. E.: Candida albicans Als1p: An adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol 44, 61-72 (2002).
39. Daniels, K. J., Lockhart, S. R., Staab, J. F., Sundstrom, P., Soll, D. R.: The adhesin HWP1 and the first daughter cell localize to the a/ a portion of the conjugation bridge during Candidda albicans mating. Mol Biol Cell 14, 4920-4930 (2003).
40. Ponton, J., Omatxebarria, M. J., Elguezabal, N., Alvarez, M., Moragues, M. D.: Immunoreactivity of the fungal cell wall. Med Mycol 39, 101-110 (2001).
41. Romani, L., in: Cytokines and Chemokines in Infectious Diseases Handbook. Eds. Kotb, M., Calandra, T. Humana Press, Totowa, 227-241 (2003).
42. Roeder, A., Kirschning, C. J., Rupec, R. A., Schaller, M., Korting, H. C.: Toll-like receptors and innate a antifungal responses. Trends Microbiol 12, 44-49 (2004).
43. Brown, G. D., Gordon, S.: Fungal β-glucans and mammalian immunity. Immunity 19, 311-315 (2003).
44. Cassone, A. De Bernardis, F., Ausiello, C. M., Gomez, M. J., Boccanera, M., La Valle, R., Torosantucci, A.: Immunogenic and protective Candida albicans constituents. Res Immunol. 149, 289-299 (1998).
45. Deepe, G. S. Jr.: Prospects for the development of fungal vaccines. Clin Microbiol Rev 10, 585-596 (1997).
46. Gomez, M. J., Maras, B., Barca, A., La Valle, L., Barra, D., Cassone, A.: Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen Candida albicans. Infect Immun 68, 694-701 (2000).
47. Nisini, R., Romagnoli, G., Gomez, M. J., La Valle, R., Torosantucci, A., Mariotti, S., Teloni, R., Cassone, A.: Antigenic properties and processing requirements of 65 kDa mannoprotein, a major antigen target of anti-Candida human T-cell response, as disclosed by specific human T-cell clones. Infect Immun 69, 3728-3736 (2001).
48. Ramage, G., Vande Walle, K., Wickes, B. L., Lopez-Ribot, J. L.: Biofilm formation by Candida dubliniensis. J Clin Microbiol 39, 3234-3240 (2001).
49. Douglas, L. J.: Medical importance of biofilms in Candida infections. Rev Iberoam Micol 19, 139-143 (2002).
50. Adam, B., Baillie, G. S., Douglas, L. J.: Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol 51, 344-349 (2002).
51. Davey, M. E., O'Toole, G. A.: Microbial biofilms: From ecology to molecular genetics. Microbiol Mol Biol Rev 64, 847-867 (2000).
52. Douglas, L. J.: Candida biofilms and their role in infection. Trends Microbiol 11, 30-36 (2003).
53. Donlan, R. M.: Biofilms: Microbial life on surfaces. Emerg Infect Dis 8, 1-19 (2002).
54. Lewis, K.: Riddle of biofilm resistance. Antimicrob Agents Chemother 45, 999-1007 (2001).
55. Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R.: In vitro activity of caspofungin against Candidaalbicans biofilm. Antimicrob Agents Chemother 46, 3591-3596 (2002).
56. Mah, T.-F. C., O'Toole, G. A.: Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9, 34-39 (2001).
57. Baillie, G. S., Douglas, L. J.: Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 46, 397-403 (2000).
58. Baillie, G. S., Douglas, L. J.: Iron-limited biofilms of Candida albicans and their susceptibility to amphotericin B. Antimicrob Agents Chemother 42, 2146-2149 (1998).
59. Baillie, G. S., Douglas, L. J.: Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 42, 1900-1905 (1998).
60. Donlan, R. M., Costerton, J. W.: Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15, 167-193 (2002).
61. Maira-Litran, T.: Expression of the multiple antibiotic resistance operon (mar) during growth of Escherichia coli as a biofilm. J Appl Microbiol 88, 243-247 (2000).
62. Brooun, A.: A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 44, 640-646 (2000).
63. Ramage, G. et al.: Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 49, 973-980 (2002).
64. White, T. C., Kieren, A. M., Bowden, R. A.: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11382-11402 (1998).
65. Borst, P.: Genetic mechanisms of drug resistance. A review, Acta Oncologica 30, 87-105 (1991).
66. Hitchcock, C. A.: Resistance of Candida albicans to azole antifungal agents. Biochem Soc Trans 21, 1039-1047 (1993).
67. Boiron, P., Drouhet, E., Dupont B. L.: Entry of ketoconazole into Candida albicans. Antimicrob, Agents Chemother 31, 244-248 (1987).
68. Clark, F. S., Parkinson, T., Hitchcock, C. A., Gow, N. A. R.: Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species - possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 40, 419-425 (1996).
69. Kelly, S. L., Lamb, D. C., Corran, A. J., Baldwin, B. C., Kelly, D. E.: Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24-dien-3-beta,6-α-diol. Biochem Biophys Res Commun 207, 910-915 (1995).
70. Shimokawa, O., Nakayama, H.: Increased sensitivity of Candida albicans cells accumulating l4α-methylated sterols to active oxygen: Possible relevance to in vivo efficacies of azole antifungal agents. Antimicrob Agents Chemother 36, 1626-1629 (1992).
71. Vanden Bossche, H.: Ergosterol biosynthesis inhibitors. In: R. Prasad (ed.), Candida albicans. Springer-Verlag KG, Berlin, Germany, 239-257 (1991).
72. Bard, M., Lees, N. D., Craft T. D., Cofrin, L., Barbuch, R., Koegel, C., Loper, J. C.: Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 28, 963-967 (1993).
73. Watson, P. F., Rose, M. E., Ellis, S. W., England, H., Kelly, S. L.: Defective sterol C5-6 desaturation and azole resistance: A new hypothesis for the mode of action of azole antifungals. Biochem Biophys Res Commun 164, 1170-1175 (1989).
74. Arthington, B. A., Bennett, L. G., Skatrud, P. L., Guynn, C. J., Barbuch, R. J., Ulbright, C. E., Bard, M.: Cloning, disruption and sequence of the gene encoding yeast C-5 sterol desaturase. Gene 102, 39-44 (1991).
75. Kelly, S. L., Lamb, D. C., Kelly, D., Manning, E. N. J., Loeffler, H., Hebart, J., Schumacher U., Einsele, H.: Resistance to fluconazole and crossresistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ(5,6) desaturation. FEBS Lett 400, 80-82 (1997).
76. Vanden Bossche, H., Marichal, L., Le Jeune, P., Coene, M. C. Gorrens, J., Cools, W.: Effects of itraconazole on cytochrome P-450-dependent sterol 14α-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 37, 2101-2105 (1993).
77. Lamb, D. C., Kelly, D. E., Baldwin, B. C., Gozzo, F., Boscott, P., Richards, W. G., Kelly, S. L.: Differential inhibition of Candida albicans CYP51 with azole antifungal stereoisomers. FEMS Microbiol Lett 149, 25-30 (1997).
78. Lamb, D. C., Kelly, D. E., Schunck, W. H., Shyadehi, A. Z., Akhtar, M., Lowe, D. J., Baldwin, B. C., Kelly, S. L.: The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem 272, 5682-5688 (1997).
79. Venkateswarlu, K., Denning, D. W., Kelly, S. L.: Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. J Med Vet Mycol 35, 19-25 (1997).
80. Lees, N. D., Broughton, M. C., Sanglard, D., Bard, M.: Azole susceptibility and hyphal formation in a cytochrome P450-deficient mutant of Candida albicans. Antimicrob Agents Chemother 34, 831-836 (1990).
81. Cutler, J. E.: Putative virulence factors of Candida albicans. Annu Rev Microbiol 45, 187-218 (1991).
82. Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J. Stevens, D. A., Warnock, D. W., Kelly, S. L.: Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 41, 1364-1368 (1997).
83. Joseph-Horne, T., Hollomon, D. W.: Molecular mechanisms of azole resistance in fungi. FEMS Microbiol Lett 149, 141-149 (1997).
84. Ishida, N., Aoyama, Y., Hatanaka, R., Oyama, Y., Imajo, S., Ishiguro, M., Oshima, T., Nakazato, H , Noguchi, T., Maitra, U. S., Mohan, V. P., Sprinson, D. B., Shida, Y.: A single amino acid substitution converts cytochrome P450(14DM) to an inactive form, cytochrome P450SG1: Complete primary structures deduced from cloned DNAS. Biochem Biophys Res Commun 155, 317-323 (1988).
85. Yoshida, Y., Aoyama, Y., Nishino, T., Katsuki, H., Maitra, U. S., Mohan, V. P., Sprinson, D. B.: Spectral properties of a novel cytochrome P450 of a Saccharomyces cerevisiae mutant SG1, a cytochrome P450 species having a nitrogenous ligand trans to thiolate. Biochem Biophys Res Commun 127, 623-628 (1985).
86. Loffler, J., Kelly, S. L., Hebart, H., Schumacher, U., LassFlorl, C., Einsele, H.: Molecular analysis of CYP51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 151, 263-268 (1997).
87. Lamb, D. C., Kelly, D. E., Baldwin, B. C., Gozzo, F., Boscott, P., Richards, W. G., Kelly, S. L.: Differential inhibition of Candida albicans CYP51 with azole antifungal stereoisomers. FEMS Microbiol Lett 149, 25-30 (1997).
88. Shyadehi, A. Z., Lamb, D. C., Kelly, S. L., Kelly, D. E., Schunck, W. H., Wright J. N., Corina, D., Akhtar, M.: The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14α-demethylase of Candida albicans (other names are lanosterol 14α-demethylase, P-450(14DM) and CYP51). J Biol Chem 271, 12445-12450 (1996).
89. Venkateswarlu, K., Kelly, D. E., Kelly, S. L.: Characterization of Saccharomyces cerevisiae CYP51 and a CYP51 fusion protein with NADPH cytochrome P-450 oxidoreductase expressed in Escherichia coli. Antimicrob Agents-Chemother 41, 776-780 (1997).
90. Sanglard, D., Ischer, F., Koymans, L., Bille, J.: Amino acid substitutions in the cytochrome P450 lanosterol 14α-demethylase ( CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42, 241-253 (1998).
91. Albertson, G. D., Niimi, M., Cannon, R. D., Jenkinson, H. F.: Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 40, 2835-2841 (1996).
92. Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., Bille, J.: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39, 2378-2386 (1995).
93. White, T. C.: Increased mRNA levels of ERG16, CDR and MDR1 correlate with increases in azole resistance in Candida albicans isolates from an HIV-infected patient. Antimicrob Agents Chemother 41, 1482-1487 (1997).
94. Chen, C., Turi, T. G., Sanglard, D., Loper, J. C.: Isolation of the Candida tropicalis gene for P450-lanosterol demethylase and its expression in Saccharomyces cerevisiae. Biochem Biophys Res Commun 146, 1311-1317 (1987).
95. Doignon, F., Aigle, M., Ribereau, G. P.: Resistance to imidazoles and triazoles in Saccharomyces cerevisiae as a new dominant marker. Plasmid 30, 224-233 (1993).
96. Kalb, V. F., Loper, J. C., Dey, C. R., Woods, C. W., Sutter, T. R.: Isolation of a cytochrome P450 structural gene from Saccharomyces cerevisiae. Gene 45, 237-245 (1986).
97. Kenna, S., Bligh, H. F., Watson, P. F., Kelly, S. L.: Genetic and physiological analysis of azole sensitivity in Saccharomyces cerevisiae. J Med Vet Mycol 27, 397-406 (1989).
98. White, T. C.: The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α-demethylase in Candida albicans. Antimicrob Agents Chemother 41, 1488-1494 (1997).
99. Odds, F. C.: Candida and candidosis. A review and bibliography. Bailliere Tindall, London, United Kingdom (1988).
100. Lockhart, S. R., Fritch, J. J., Meier, A. S., Schroppel, K., Srikantha, T., Galask, R., Soll, D. R.: Colonizing populations of Candida albicans are clonal in origin but undergo micro-evolution through C-1 fragment reorganization as demonstrated by DNA fingerprinting and C-1 sequencing. J Clin Microbiol 33, 1501-1509 (1995).
101. Bard, M., Bruner, D. A., Pierson, C. A., Lees, N. D., Biermann, B., Frye, L., Koegel, C., Barbuch, R.: Cloning and characterization of ERG25, the Saccharomyces cerevisiae gene encoding C-4 sterol methyl oxidase. Proc Natl Acad Sci USA 93, 186-190 (1996).
102. Kelly, S. L., Lamb, D. C., Baldwin, B. C., Corran, A. J., Kelly, D. E.: Characterization of Saccharomyces cerevisiae CYP61, sterol Δ(22)-desaturase and inhibition by azole antifungal agents. J Biol Chem 272, 9986-9988 (1997).
103. Lees, N. D. Skaggs, B., Kirsch, D. R., Bard, M.: Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae - a review. Lipids 30, 221-226 (1995).
104. Scherer, S., Ran, Y.: Candida albicans information. Web page. http://alces.med.umn.edu/Candida.html. (1996).
105. Burgener-Kairuz, P., Zuber, J. P., Jaunin, P., Buchman, T. G., Bille, J., Rossier, M.: Rapid detection and identification of Candida albicans and Torulopsis (Candida) glabrata in clinical specimens by species-specific nested PCR amplification of a cytochrome P450 lanosterolα - demethylase (L1A1) gene fragment. J Clin Microbiol 32, 1902-1907 (1994).
106. Geber, A., Hitchcock, C. A., Swartz, J. E., Pullen, F. S., Marsden, K. E., Kwon-Chung, K. J., Bennett, J. E.: Deletion of the Candida glabrata ERG3 and ERG11 genes-effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother 39, 2708-2717 (1995).
107. Chen, C., Turi, T. G., Sanglard, D., Loper, J. C.: Isolation of the Candida tropicalis gene for P450 lanosterol demethylase and its expression in Saccharomyces cerevisiae. Biochem Biophys Res Commun 146, 1311-1317 (1987).
108. Kelly, S. L., Larab, D. C., Kelly, D. E., Loeffler, J., Einsele, H.: Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348, 1523-1524 (1996).
109. Kelly, S. L., Lam, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., Einsele, H.: Resistance to fluconazole and crossresistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ(5,6) desaturation. FEBS Lett 400, 80-82 (1997).
110. Joseph-Horne, T., Manning, N. J., Hollomon, D., Kelly S. L.: Defective sterol Δ5(6) desaturase as a cause of azole resistance in Ustilago maydis. FEMS Microbiol Lett 127, 29-34 (1995).
111. Joseph-Horne, T., Hollomon, D., Loeffler, R. S., Kelly, S. L.: Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother 39, 1526-1529 (1995).
112. Venkateswarlu, K., Taylor, M., Manning, N. J., Rinaldi, M. G., Kelly, S. L.: Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 41, 748-751. (1997).
113. Vanden Bossche, H., Warnock, W., Dupont, B., Kerridge, D., Sen, G., Improvisi, S. L., Marichal, P., Odds, C. F., Provost F., Ronin, O.: Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 32, 189-202 (1994).
114. Prasad, R., Gaur, A., Gaur, M., Komath, S.: Efflux pumps in drug resistance of Candida. Infectious Disorders Drug Targets 6, 69-83 (2006).
115. Higgins, C. F.: ABC transporters: Physiology, structure and mechanism - an overview. Res Microbiol 152 205-210 (2001).
116. Prasad, R., Worgifosse, P. D., Goffeau, A., Balzi, E.: Molecular cloning and characterization of a novel gene of Candida albicans CDR1 conferring, multiple resistance to drugs and antifungals. Curr Gent 27, 320-329 (1995).
117. Franz, R., Michel, S., Morschhauser, J.: A fourth gene from the Candida albicans CDR family of ABC transporters. Gene 220, 91-98 (1998).
118. Cannon, R. D., Tsao, S., Ong, S., Niimi, K., Lamping, E., Monk, B. C., Holmes, A. R.: Allelic variation affecting drug pump function in Candida albicans. ASM conference on Candida and Candidiasis abstract no. 147(C). March 18-22 (2004) Austin, TX.
119. Woodahl, E. L., Ho, R. J.: The role of MDR1 genetic polymorphisms in individual variability in P-glycoprotein expression and function. Curr Drug Metab 5, 11-19 (2004).
120. Wada, S., Niimi, M., Niimi, K., Holmes, A. R., Monk, B. C., Cannon, R. D., Uehara, Y.: Candida giabarata ATP-binding cassette transporter, Cdr1p and Pdh1p expressed in a Saccharomyces cerevisiae strain deficient in membrane transporter show phosphorylation dependent pumping properties. J Biol Chem 272, 46809-46821 (2002).
121. Higgins, C. F., Linton, K. J.: The ATP switch model for ABC transporters. Nat Struct Mol Biol 11, 918-926 (2004).
122. Walker, J. E., Sarsate, M., Runswick, M., Gay, N. L: Distantly related sequences in the α-and β-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1, 945-951 (1982).
123. Schneider, E., Hunke, S.: ATP-binding-cassette (ABC) transport systems: Functional and structural aspects of the ATP-hydrolyzing subunits/ domains FEMS. Microbiol Rev 22, 1-20 (1998).
124. Jha, S., Karnani, N., Dhar, S. K., Mukhopadhyay, K., Shukla S., Saini, P., Mukhopadhyay, G., Prasad, R.: Purification and characterization of the N-terminal nucleotide binding domain of an ABC drug transporter of Candida albicans: uncommon cysteine 193 of Walker A is critical for ATP hydrolysis. Biochem 42, 10822-10832 (2003).
125. Loo, T. W., Bartlett, M. C., Clarke, D. M.: Drug binding in human p-glycoprotein causes conformational changes in both nucleotide-binding domains. J Biol Chem 278, 1575-1578 (2003).
126. Harry, J. B., Song, J. L., Lyons, C. N., White, T. C.: Transcription initiation of genes associated with resistance in Candida albicans. Med Mycol 40, 73-81 (2003).
127. Krishnamurthy, S., Chatterjee, U., Gupta, V., Prasad, R., Das, P., Snehlata, P., Hasnain, S. E., Prasad, R.: Deletion of transmembrane domain 12 of CDR1, a multidrug transporter from Candida albicans, leads to altered drug specificity: expression of a yeast multidrug transporter n baculovirus expression system. Yeast 14, 535-550 (1998).
128. Beaudet, L. Gros, P.: Functional dissection of P-glycoprotein nucleotide-binding domains in chimeric and mutant proteins. Modulation of drug resistance profiles. J Biol Chem 270, 17159-17170 (1995).
129. Rai, V., Shukla, S., Jha, S., Komath, S. S., Prasad, R.: Functional characterization of N-terminal nucleotide binding domain (NBD-1) of a major ABC drug transporter Cdr1p of Candida albicans: Uncommon but conserved Trp326 of Walker B is important for ATP binding. Bichemistry 44, 6650-6661 (2005).
130. Zhou, T., Rosen, B. P.: Tryptophan fluorescence reports nucleotide-induced conformational changes in a domain of the ArsA ATPase. J Biol Chem 272, 19731-19737 (1997).
131. Ben-Yaacov, R., Knoller, S., Caldwell, G. A., Becker, J. M., Koltin, Y.: Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrob Agents Chemother 38, 648-652 (1994).
132. Fling, M. E., Kopf, J., Tamarkin, A., Gorman, J. A., Smith, H. A., Koltin, Y.: Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 227, 318-329 (1991).
133. Becker, J. M., Henry, L. K., Jiang, W., Koltin, Y.: Reduced virulence of Candida albicans mutants affected in multidrug resistance. Infec Immun 63, 4515-4518 (1995).
134. Gupta, V., Kohli, A. K., Krishnamurthy, S., Puri, N., Aalamgeer, S. A., Panwar, S. L., Prasad, R.: Identification of seven mutant alleles of CaMDR1, a membrane facilitator of Candida albicans which confers multidrug resistance and its in vitro transcriptional activation. Curr Genet 34, 192-199 (1998).
135. Kusch, H., Biswas, K., Schwanfelder, S., Engelmann, S., Rogers, P. D., Hecker, M., Morschhauser, J.: A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. Mol Genet Genomics 271, 554-565 (2004).
136. Ferte, J.: Analysis of tangled relationships between P-glycoprotein mediated multidrug resistant and the lipid phase of the cell membrane. Eur J Biochem 267, 277-294 (2000).
137. Mukhopadhyay, K., Kohli, A. K., Prasad, R.: Drug susceptibilities of yeast cells are affected by membrane lipid composition. Antimicrob Agents Chemother 46, 3695-3705 (2002).
138. Van Den Hazel, H. B., Pichler, H., Do Valle Matta, M. A., Leitner, E., Goffeau, A., Daum, G.: PDR16 and PDR17, two homologous genes of Sacchromyces cereviside affect lipid biosyntheis and resistance to multiple drugs. J Biol Chem 274, 1934-1941 (1999).
139. Goff, D. A., Koletar S. L., Buesching, W. J., Barnishan, J., Fass, R. J.: Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus negative patients never treated with azoles. Clin Infect Dis 20, 77-83 (1995).
140. Iwen, P. C., Kelly, D. M., Reed, E. C., Hinrichs, S. H.: Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 20, 342-347 (1995).
141. Wingard, J. R., Merz, W. G., Rinaldi, M.G., Jonhson, T. R., Karp, J. E., Saral, R.: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325, 1274-1277 (1991).
142. Nguyen, M. H., Peacock, J. E., Morris, A. J.: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100, 617-623 (1996).
143. Abi Said, D., Anaissie, E., Uzun, O., Pinzcowski, H., Vartivarian, S.: The epidemiology of hematogeneous candidiasis caused by different Candida species. Clin Infect Dis 24, 1122-1128 (1997).
144. Abbas, J., Bodey, G. P., Hanna, H. A. et al.: Candida krusei fungemia: An escalating serious infection in immunocompromised patients. Arch Intern Med 160, 2659-2664 (2000).
145. Gumbo, T., Isada, C. M., Hall, G., Karafa, M. T., Gordon, S. M.: Candida glabrata fungemia: Clinical features of 139 patients. Medicine (Balt) 78, 220-227 (1999).
146. Viscoli, C., Girmenia, C., Marinus, A. et al.: Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28, 1071-1079 (1999).
147. Musa, M. O., Eisa, A. A., Halim, M. et al.: The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immuno-compromised patients: a single institution experience over 10 years. Br J Haematol 108, 544-548 (2000).
148. Girmenia, C., Pagano, L., Corvatta, L., Mele, L., del Favero, A., Martino, P.: The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol 111, 272-276 (2000).
149. Berenguer, J., Rodriguez-Tudela, J. L., Richard, C. et al.: Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Balt) 76, 256-265 (1997).
150. Wood, G. M., McCormack, J. G., Muir, D. B. et al.: Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 14, 1027-1033 (1992).
151. Iwen, C., Rupp, M. E., Langnas, A. N., Reed, E. C., Hinrichs, S. H.: Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 26, 1092-1097 (1998).
152. Canuto, M. M., Rodero, F. G.: Antifungal drug resistance to azoles and polyenes. Lancet Infectious Disease 2, 550-563 (2002).
153. Gutierrez, F., Wall, P. G., Cohen, J.: An audit of the use of antifungal agents. J Antimicrob Chemother 37, 175-185 (1996).
154. Rex, J. H., Walsh, T. J., Sobel, J. D. et al.: Practice guidelines for the treatment of candidiasis. Clin Infect Dis 30, 662-678 (2000).